Slide 1

Treatment of diabetes mellitus in hospitals Done by: Fatimah Al-Shehri Pharm.D Candidate King Abdulaziz university Supervised by: Dr.Hani Hassan Clinical pharmacist/internal medicine.

Slide 2

Outline -Introduction. -Goals in the hospital settings. -Prevention of hyperglycemia and hypoglycemia. -Treatment.

Slide 3

Introduction: Glycemic control is unstable in hospitalized patients because of : - Stress of the illness or procedure. - Concomitant changes in dietary intake - Physical activity. -Frequent interruption of the patient's usual antihyperglycemic regimen.

Slide 4

Goals in hospitals : - Avoid hypoglycemia. -Avoid severe hyperglycemia. -Avoid volume depletion --Avoid electrolyte abnormalities. -Ensure adequate nutrition.

Slide 5

Avoidance of hypoglycemia: Hypoglycemia (ie, serum glucose conc

Slide 6

Avoidance of hyperglycemia: It is a long-standing clinical observation when blood glucose sugar is above 110mg/dl. Hyperglycemia consequences : - Volume and electrolyte disturbances mediated by osmotic diuresis. - caloric and protein loss in under-insulinized patients. -Immune and neutrophil function is impaired.

Slide 7

Glycemic targets in hospitals: Target of the blood sugar deepens on the severity of the illness. A-Critically ill patients. B-Non-critically ill patients.

Slide 8

:Non-critically ill Glycemic goals in non-critically ill patients :

Slide 9

Treatment

Slide 10

Treatment of hyperglycemia in hospital: 1- The type of diabetes. 2-The patient's current BG concentrations. 3-Prior treatment. 4-The severity of illness. 5- The expected caloric intake during the acute episode..

Slide 11

Treatment options : - Insulin. - Oral hypoglycemic.

Slide 12

Slide 13

Slide 14

Slide 15

1-Insulin : Types of insulin: 1-long-acting insulin: such as glargine or detemir. 2-Intermediate-acting insulin:such as NPH. 3- Premeal rapid or short-acting insulin such as :regular insulin, aspart, lispro.

Slide 16

Insulin analogs:

Slide 17

Slide 18

Insulin regimen used in hospitalized patients : 1-Fixed dose regimen: -Basal bolus insulin regmin (BBI). -Regular regimen). 2-Sliding scale insulin regimen.( SSI) 3-Insulin correction. 3-Insulin infusion.

Slide 19

1-Basal bolus insulin regimen : 1-Basal bolus regimen: Basal Insulin: Prevents between meal and overnight hyperglycemia Bolus insulin: Limits hyperglycemia after meals.

Slide 20

1-Basal bolus insulin regimen: Proactive Approach: Anticipate major change in blood glucose levels and prevent them from occurring Insulin therapies that mimic physiological release of insulin. Individualized basal-bolus insulin therapies (BBI)

Slide 21

:2-Sliding-scale insulin SSI: involves use of regular insulin or a rapid-acting insulin analogue provided without any other scheduled short-acting or long-acting insulin.

Slide 22

2-Sliding scale insulin: Urine glucose monitoring. Boil urine sample with solution containing copper sulfate. 1934 Sliding Scale by Elliot Joslin.

Slide 23

3-Todays Insulin Sliding Scale: Blood glucose monitoring, Use of glucometer. Regimens for rapid-acting or short-acting insulin. Schedule:TID-QID. Units :Blood glucose level : 0 Unit.20

Slide 24

Which sliding scale :

Slide 25

Advantages & Disadvantages of ISS: AdvantagesDisadvantages Not individualized Creates a roller coaster effect Reactive Approach Not evidence based practice Can initiate right away SimpleConvenient Umpierrez GE, Palacio A, Smiley D. Sliding scale insulin use: myth or insanity? Am J Med 2007; 120: 563 567

Slide 26

2-Insulin sliding scale :

Slide 27

SSI - Traditional Insulin Sliding Scales: No basal insulin. - Supplemental Scale or Correction Scale: ISS + (basal insulin +/- bolus insulin) Primarily used AS: dose-finding strategy (bolus insulin dosage) -As a supplement when rapid changes in insulin requirements (i.e. stress or illness)

Slide 28

ISS vs. BBI?

Slide 29

Evidence against SSI:

Slide 30

Rabbit trial 2:

Slide 31

Evidence against the SSI :

Slide 32

Although sliding scale insulin regimens are prescribed for the majority of inpatients with diabetes, they appear to provide no Benefit.. in fact, when used without a standing dose of intermediate- acting insulin, they are associated with an increased rate of hyperglycemic episodes.

Slide 33

Evidence against SSI: MJA 2012; 196: 266269 doi: 10.5694/mja11.10853

Slide 34

Mean change in BGL from baseline in the two insulin therapy groups. MJA 2012; 196: 266269 doi: 10.5694/mja11.10853

Slide 35

Conclusion : under routine clinical conditions, implementation of a BBI protocol to manage hyperglycaemia in hospitalised patients resulted in a lower mean daily BGL than did SSI. BBI is associated with an increase in mild, but not severe, hypoglycaemia. We recommend that protocols for inpatient glycaemic control based around BBI be widely implemented.

Slide 36

Time to stop SSI: 1-Unaware of problems associated with ISS 2- Unwilling to make changes to therapies initiated by another physician 3- Lack of evidence Long-term care (LTC) setting

Slide 37

Slide 38

QUESTION: AS clinical pharmacist, When making your recommendation to the physician, what information might you want to include about SSI and BBI ? A-Basal-bolus is a proactive approach to management, preventing hyperglycemia without increasing the risk of hypoglycemia. B-The use of insulin sliding scale is not evidence-based practice. C-Insulin sliding scale is most likely the medication causing the patient to fall and affecting patients ability to focus. D- All of the above.

Slide 39

:3- Correction insulin The dose of correction insulin should be individualized based upon relevant patient characteristics such as : - Previous level of glucose control. - Previous insulin requirements. - The carbohydrate content of meals. Correctional insulin needs : - 1800 rule: 1800/TDI=number of mg/dl of glucose lowering per 1 unit of rapid acting insulin. ((1 unit of rapid actin insukin will reduce the BG concentration by x mg/dl. - 1500 rule :1500/TDI.

Slide 40

:3- Correction insulin Correction insulin alone may also be used : - As initial insulin therapy in patients with type 2 diabetes previously treated at home with diet or an oral agent, who will not be eating regularly during hospitalization. It is typically administered every six hours as regular insulin. However, if the patient is eating and finger stick glucoses are consistently elevated (>180mg/dL [10.0 mmol/L]) : (basal-bolus regimen).

Slide 41

Insulin requirements: 50 % of the total daily dose can be given as BI. The remaining 50% can be given in equally divided doses prior to meals (1/3 prior to each meal). 2-Regular insulin:1-Basal bolus regimen: 70%(2/3) of the dose given in the morning. 30%(1/3) of the dose given in the evening. 50% basal insulin. 50% bolus insulin. e.g: 25 units/day (NPH). - 16 units in the morning. - 9 units in the evening. e.g: 25 units/day. - Glargin:12.5 unit as basal -Lispro: 12.5 ( 4.4.4 ) as bolus.

Slide 42

http://diabetesmanager.pbworks.com/w/page/17680263/Management%20of%20the%20Hospitalized%20Diabeti c%20Patient

Slide 43

4-Insulin infusion: Insulin infusions are typically used in critically ill ICU patients, rather than in patients on the general medical wards of the hospital.

Slide 44

Oral hypoglycemic agents:

Slide 45

References : http://diabetes.niddk.nih.gov/dm/pubs/causes. http://care.diabetesjournals.org/content/29/sup pl_1/s43.full

Slide 46

Slide 47